COVID-19 Vaccination and The Eye

Wang, Michael T.M.; Niederer, Rachael L; McGhee, Charles N J; Danesh‐Meyer, Helen V.

doi:10.1016/j.ajo.2022.02.011

Cited by 43 publications

(44 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The estimated crude reporting rates in this study are comparable to the report by Wang and colleagues, who evaluated the data from the Australia Therapeutic Goods Administration Database of Adverse Event Notifications, the Canada Vigilance Adverse Reaction Database, the European Union Medicines Agency (EudraVigilance) System, and the United Kingdom Medicines and Healthcare Products Regulatory Agency between December 2020 and August 2021. 25 In this study cohort, a substantial proportion of the patients were women and between 50-70 years. The data analysis of this cohort shows that the patients typically presented with signs of glaucoma in the first 24-48 hours post-vaccination and the incidence was higher after the first dose.…”

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Singh

Parmar

Ichhpujani

2022

Preprint

View full text Add to dashboard Cite

Objective: To evaluate glaucoma cases reported post-COVID-19 vaccination and describe the clinical presentations in these cases. Design: An analysis of the Centers for Disease Control and Prevention (CDC) Vaccine Adverse Event Reporting System (VAERS) database Participants: The study includes 161 individuals who were reported for glaucoma after administration of COVID-19 vaccines [BNT162b2 (Pfizer-BioNTech), mRNA-1273 (Moderna) and Ad26.COV2.S (Janssen)] between December 2020 and April 2022. Main Outcome Measures: Estimated crude reporting rate of glaucoma, clinical presentations, onset duration and associated risk factors. Results: A total of 2,061,557,270 doses of COVID-19 vaccines were administered during the study timeframe. During this period, 161 glaucoma cases were reported with an estimated crude reporting rate (per million doses) of 0.09, 0.06 and 0.07 for BNT162b2, mRNA-1273 and Ad26.COV2.S, respectively. The majority of patients (n=130, 80.7%) received BNT162b2, vaccine, while 27 patients (16.8%) received mRNA-1273 and four patients (2.5%) received rAd26.COV2.S vaccines. The mean age of patients in the cohort was 60.41+/-17.56 years and 67.7% (n=109) were women. More than half (56.6%) were reported within the first week after vaccination. The glaucoma onset interval was significantly shorter in patients who received BNT162b2 and rAd26.COV2.S vaccines compared to mRNA-1273 (p=0.013). A higher risk of glaucoma incidence was observed in the short term in patients who received BNT162b2 vaccines compared to mRNA-1273 (p=0.05). In patients vaccinated with mRNA-1273, a significantly higher frequency of glaucoma cases was reported in older patients (p=0.047) compared to younger age groups. Conclusions: The CDC-VAERS data suggest an extremely low safety concern for glaucoma on receiving BNT162b2, mRNA-1273, or Ad26.COV2.S vaccines. The onset interval of adverse events was shorter in patients who received BNT162b2 and rAd26.COV2.S vaccines compared to mRNA-1273. The glaucoma cases after mRNA-1273 vaccination were more commonly reported in older patients. These findings are subject to the limitations of passive reporting systems, under reporting and presumptive case definition, and should be considered preliminary without the medical record analysis for establishing a definitive diagnosis.

show abstract

Section: Discussionmentioning

confidence: 88%

Section: Discussionmentioning

confidence: 99%

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Singh

Parmar

Ichhpujani

2022

Preprint

View full text Add to dashboard Cite

show abstract

“…While the prognosis for BCVA and for graft survival were good overall, 25% of the PKP eyes with acute corneal allograft rejection following SARS-CoV-2 vaccination had incomplete resolution or graft failure, and although the risk of graft failure due to rejection after EK is relatively low (Price et al, 2018;Stulting et al, 2018) as many as 20-25% of EK eyes may be at risk of decreased corneal transparency or graft failure due to immune reaction after SARS-CoV-2 vaccination. The main strengths of our study are: (1) Our database search enabled us to find the largest number of reported cases (more than the previous summary of evidence), (Wang et al, 2022) and is the only study summarizing evidence including published data in 2022, being the most up to date database search available; and (2) we provide an in-depth analysis of potentially confounding factors and of the clinical outcomes of acute corneal allograft rejection following SARS-CoV-2 vaccination. The main limitation of this review is the fact that only case reports or small case series were found in the literature search.…”

Section: Discussionmentioning

confidence: 99%

Acute corneal allograft rejection following SARS‐CoV‐2 vaccination–A systematic review

Moura-Coelho

Cunha

Papa-Vettorazzi

et al. 2022

Acta Ophthalmologica

View full text Add to dashboard Cite

Coronavirus disease , the ongoing pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is still a major public health challenge. The rapid development of a number of vaccines for SARS-CoV-2 was crucial for the prevention of severe manifestations of the disease and death due to COVID-19. SARS-CoV-2 has the potential to affect many tissues and systems, including ocular tissues and adnexa. (Cunha et al., 2020;Lin et al., 2021) The watchful control of adverse events (AEs) of the novel vaccines also led to the detection of rare ocular AEs after SARS-CoV-2 vaccination affecting any ocular structure and the optic nerve. (

show abstract

“…We reported six patients with infectious ocular disorders after the first dose of inactivated COVID-19 vaccine, including four cases of ARN, one case of herpetic neuritis, and one case of ocular toxoplasmosis. Herpetic eye disorders have previously been reported after mRNA and vector vaccines, and presented as conjunctivitis, stromal keratitis, and herpes zoster ophthalmicus [29]. ARN has previously been reported to occur after the mRNA COVID-19 vaccine in immunocompetent individuals [30,31], or in COVID-19 positive patients [32].…”

Section: Discussionmentioning

confidence: 99%

Ocular Adverse Events after Inactivated COVID-19 Vaccination

et al. 2022

Vaccines

View full text Add to dashboard Cite

Purpose: To report the clinical characteristics of ocular adverse events that have occurred, in China, after vaccination with inactivated COVID-19 vaccines. Methods: A retrospective cross-sectional observational study was conducted of ocular disorders that occurred within 15 days from any dose of an inactivated COVID-19 vaccine. Information on gender, age, the interval between the vaccination and ocular symptoms, laterality, duration of the ocular symptoms, primary visual acuity, and clinical diagnosis were retrospectively collected. Results: Twenty-four patients were involved in the study, including 15 females and 9 males, with a mean age of 41 ± 16 years (range of 8–71 years). The patients all denied a prior history of COVID-19 infection. Ocular adverse events occurred after the first dose of vaccine in 18 patients and, after the second or third doses, in six patients. The interval between vaccination with the inactivated COVID-19 vaccine and ocular symptoms was 6 ± 5 days; six patients were bilaterally involved and 18 patients were unilaterally involved. Regarding the diagnosis, 10 patients were diagnosed with white dot syndrome (WDS), 9 patients were diagnosed with uveitis, and 5 patients were diagnosed with retinal vascular disorders. The ages of patients with WDS were younger than those with uveitis or retinal vascular disorders (32 ± 10 vs. 48 ± 18, p < 0.05). For patients diagnosed with WDS, the best-corrected visual acuity (BCVA) was 0.74 ± 0.73 LogMAR. For patients diagnosed with retinal vascular disorders or uveitis, the BCVA was 1.44 ± 1.26 LogMAR. There was no significant difference (p > 0.05). Conclusions: A relationship cannot be established between inactivated COVID-19 vaccines and ocular disorders; therefore, further investigation of the clinical spectrum of ocular adverse events after vaccination with an inactivated COVID-19 vaccine is necessary.

show abstract

COVID-19 Vaccination and The Eye

Cited by 43 publications

References 73 publications

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Glaucoma cases reported post-COVID-19 vaccination : A VAERS database analysis

Acute corneal allograft rejection following SARS‐CoV‐2 vaccination–A systematic review

Ocular Adverse Events after Inactivated COVID-19 Vaccination

Contact Info

Product

Resources

About